Volume 5, Issue 4, Pages e5 (October 2017)

Slides:



Advertisements
Similar presentations
Volume 19, Issue 5, Pages (May 2017)
Advertisements

Volume 19, Issue 5, Pages (May 2017)
Untangling P-Bodies: Dissecting the Complex Web of Interactions that Enable Tiered Control of Gene Expression  Christopher J. Kershaw, Mark P. Ashe  Molecular.
Strategy Description Discovery Validation Application
Volume 5, Issue 1, Pages (October 2013)
Volume 4, Issue 4, Pages e5 (April 2017)
Protein Networks in Alzheimer’s Disease
DAISY: Picking Synthetic Lethals from Cancer Genomes
Volume 7, Issue 1, Pages e7 (July 2018)
Molecular Subtypes of Non-muscle Invasive Bladder Cancer
Volume 165, Issue 1, Pages (March 2016)
Volume 23, Issue 4, Pages (April 2018)
Volume 25, Issue 6, Pages e4 (November 2018)
Volume 31, Issue 2, Pages (February 2017)
Understanding Tissue-Specific Gene Regulation
Volume 23, Issue 9, Pages e5 (May 2018)
Amy C. Foulkes, David S. Watson, Daniel F. Carr, John G
Volume 4, Issue 3, Pages (August 2013)
Volume 25, Issue 5, Pages e5 (October 2018)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Volume 3, Issue 1, Pages (July 2016)
Global Edgetic Rewiring in Cancer Networks
Volume 24, Issue 4, Pages (July 2018)
Integrative Multi-omic Analysis of Human Platelet eQTLs Reveals Alternative Start Site in Mitofusin 2  Lukas M. Simon, Edward S. Chen, Leonard C. Edelstein,
Volume 18, Issue 1, Pages (January 2017)
Modeling Enzyme Processivity Reveals that RNA-Seq Libraries Are Biased in Characteristic and Correctable Ways  Nathan Archer, Mark D. Walsh, Vahid Shahrezaei,
Volume 17, Issue 8, Pages (November 2016)
Untangling P-Bodies: Dissecting the Complex Web of Interactions that Enable Tiered Control of Gene Expression  Christopher J. Kershaw, Mark P. Ashe  Molecular.
Volume 24, Issue 12, Pages e5 (September 2018)
Volume 4, Issue 5, Pages e5 (May 2017)
Volume 24, Issue 8, Pages (August 2018)
Large Differences in Small RNA Composition Between Human Biofluids
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
Volume 5, Issue 4, Pages e4 (October 2017)
Volume 7, Issue 3, Pages e12 (September 2018)
Volume 22, Issue 3, Pages (January 2018)
Volume 5, Issue 4, Pages e4 (October 2017)
Volume 22, Issue 3, Pages e4 (September 2017)
Volume 4, Issue 3, Pages e3 (March 2017)
Volume 29, Issue 5, Pages (May 2016)
Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.
Volume 23, Issue 5, Pages (May 2016)
Volume 19, Issue 5, Pages (May 2017)
Distal Alternative Last Exons Localize mRNAs to Neural Projections
James M. Flanagan, Sibylle Cocciardi, Nic Waddell, Cameron N
Modeling Enzyme Processivity Reveals that RNA-Seq Libraries Are Biased in Characteristic and Correctable Ways  Nathan Archer, Mark D. Walsh, Vahid Shahrezaei,
Volume 15, Issue 12, Pages (June 2016)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Brandon Ho, Anastasia Baryshnikova, Grant W. Brown  Cell Systems 
Volume 26, Issue 12, Pages e5 (March 2019)
LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.
Network-Based Coverage of Mutational Profiles Reveals Cancer Genes
Analysis of renal transcriptome responses identifies LX-regulated transcriptional networks. Analysis of renal transcriptome responses identifies LX-regulated.
Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.
Volume 2, Issue 3, Pages (March 2016)
Volume 7, Issue 6, Pages e3 (December 2018)
Stephen Bridgett, James Campbell, Christopher J. Lord, Colm J. Ryan 
Distinct molecular and clinical correlates of H3F3A mutation subgroups
Integrated mRNA and microRNA expression and DNA methylation clusters.
PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.
Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients.
Expression of 20 genes significantly associated with reduced survivability in GBM is shown across 33 TCGA diseases. Expression of 20 genes significantly.
Volume 26, Issue 11, Pages e6 (March 2019)
Volume 28, Issue 3, Pages e7 (July 2019)
Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery  Chen-Tsung Huang, Chiao-Hui Hsieh, Yun-Hsien Chung, Yen-Jen Oyang, Hsuan-Cheng.
Collin Tokheim, Rachel Karchin  Cell Systems 
The Molecular Signatures Database Hallmark Gene Set Collection
Volume 28, Issue 4, Pages e6 (July 2019)
Synthetic lethality of ROS1 inhibition in E-cadherin–deficient breast tumor cell lines. Synthetic lethality of ROS1 inhibition in E-cadherin–deficient.
Composition and Function of Mutant Swi/Snf Complexes
Presentation transcript:

Volume 5, Issue 4, Pages 399-409.e5 (October 2017) A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events  Colm J. Ryan, Susan Kennedy, Ilirjana Bajrami, David Matallanas, Christopher J. Lord  Cell Systems  Volume 5, Issue 4, Pages 399-409.e5 (October 2017) DOI: 10.1016/j.cels.2017.09.011 Copyright © 2017 The Author(s) Terms and Conditions

Cell Systems 2017 5, 399-409.e5DOI: (10.1016/j.cels.2017.09.011) Copyright © 2017 The Author(s) Terms and Conditions

Figure 1 BrCa-Core Complex Discovery (A) An integrated protein-protein interaction network is combined with tumor proteomic profiles to identify sets of densely connected proteins that display correlated expression profiles across tumor proteomes. By comparing the results with those derived from randomly relabeled protein interaction networks, we can estimate the false discovery rate (FDR). The BrCa-Core set contains 285 complexes at an estimated FDR of 10%. (B) BrCa-Core 17: the COP9 signalosome. The heatmap on the right shows protein expression of all subunits across 77 breast tumor proteomes. These have been sorted based on the mean abundance of all subunits. (C) BrCa-Core 14: the conserved oligomeric Golgi (COG) complex. (D) BrCa-Core 47 contains the ORC2–5 complex found in CORUM with the addition of LRWD1. (E) BrCa-Core 25, the COPI complex. (F) BrCa-Core 48, the EARP complex with the recently identified EARP interactor TSSC1. (G) BrCa-Core 26, the Commander complex. Cell Systems 2017 5, 399-409.e5DOI: (10.1016/j.cels.2017.09.011) Copyright © 2017 The Author(s) Terms and Conditions

Figure 2 Subtype-Specific Complex Expression (A) Heatmap displaying protein expression levels of specific BrCa-Core complexes. Tumor samples are grouped according to subtype (using IHC markers), indicated on top of the heatmap. Genes are grouped into specific complexes indicated on the right of the heatmap. Shown are the expression levels taken from Tyanova et al., 2016 (used for validation). These expression levels have been normalized such that the maximum expression level is 1 and minimum is 0. Heatmap for the discovery dataset (Mertins et al., 2016) is shown in Figure S2A. Complexes differentially expressed in specific subtypes are highlighted with boxes colored to match the subtype they are differentially expressed in. (B) Boxplots displaying the subtype-specific protein expression levels of selected subunits of the COPI complex (BrCa-Core 25) in the Tyanova et al. dataset (top) and TCGA dataset (bottom). These boxplots show median and interquartile range and are colored according to sample subtype (matching Figure 2A). Cell Systems 2017 5, 399-409.e5DOI: (10.1016/j.cels.2017.09.011) Copyright © 2017 The Author(s) Terms and Conditions

Figure 3 Subunit Loss Is Associated with a Reduction in Protein Complex Expression (A) Model displaying a potential series of events; mutation or deletion of one subunit is associated with reduced protein abundance of that subunit and potentially a reduction in expression of the entire complex. (B) Mutation or deletion of EXOC2 is associated with a reduction in protein abundance of the exocyst complex (BrCa-Core 27). Boxplots display the protein abundance of different subunits partitioned according to EXOC2 status. Each boxplot shows the median and interquartile range. Genes marked with a star indicate those whose proteomic abundance is significantly lower (one-sided Mann-Whitney test, p < 0.05) in samples with EXOC2 mutation/deletion. (C) CDH1 mutation is associated with a reduction in protein expression of an adherens junction complex (BrCa-Core 30). Legend as for (B). Cell Systems 2017 5, 399-409.e5DOI: (10.1016/j.cels.2017.09.011) Copyright © 2017 The Author(s) Terms and Conditions

Figure 4 E-cadherin Loss Is Associated with Reduced Expression of an Adherens Junction Complex (A) In tumor samples, CDH1 mutation is associated with a decrease in mRNA and protein expression of CDH1 but only of protein expression for CTNNA1 and CTNNB1. All expression and RPPA measurements are Z scores. Boxplots show median and interquartile range. p values calculated using a Mann-Whitney test. mRNA measurements for all three genes were available for 992 tumors, RPPA data for CDH1, and CTNNB1 were available for 760 tumors, while RPPA data for CTNNA1 were available for only 64 tumors. (B) Protein expression measured in a pair of isogenic MCF7 cell lines that differ by CDH1 status. Shown are the log2 label-free quantification intensities. p values are calculated using a two-sided heteroscedastic t test. Cell Systems 2017 5, 399-409.e5DOI: (10.1016/j.cels.2017.09.011) Copyright © 2017 The Author(s) Terms and Conditions